Systimmune Inc.
Clinical trials sponsored by Systimmune Inc., explained in plain language.
-
New drug trial offers hope for Tough-to-Treat neuroendocrine cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called BL-M14D1 in 120 patients with advanced small cell lung cancer and other neuroendocrine cancers that have spread and stopped responding to standard treatments. The main goals are to find the safest dose and see how the body proce…
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Experimental drug offers hope for advanced cancers with no other options
Disease control Recruiting nowThis early-stage trial is testing a new drug called BL-M05D1 in people with advanced cancers that have spread and stopped responding to standard treatments. The study will enroll 120 patients with specific cancers like stomach, pancreatic, and esophageal cancer to determine the s…
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New weapon tested in war on advanced cancers
Disease control Recruiting nowThis is the first study in people to test a new drug called BL-B01D1. It aims to find a safe dose and see if it can help control advanced cancers that have spread or cannot be removed by surgery. The trial will enroll about 470 adults with various solid tumors, including lung, br…
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
First-in-Human trial launches for aggressive leukemia patients out of options
Disease control Recruiting nowThis is the first human study of an experimental drug called BL-M11D1 for adults with acute myeloid leukemia (AML) that has returned or stopped responding to standard treatments. The main goal is to find a safe dose and see how the body processes the drug, while also checking for…
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New experimental drug targets multiple advanced cancers in groundbreaking trial
Disease control Recruiting nowThis early-stage study is testing a new drug called BL-M07D1 for people with advanced cancers that have a specific marker called HER2. The trial aims to find the safest dose and see if the drug helps control cancer growth in patients who have already tried standard treatments. Re…
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Mar 17, 2026 13:08 UTC